BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia
Stock Information for BioXcel Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.